NASDAQ OMX

First quantitative M&A brand study of S&P Global 100 shows 74 percent rebrand post-acquisition; sector, deal size, and appetite key factors

Dela
  • The Landor M&A Brand Study is a first in providing an objective benchmark for the relationship between acquisitions and brand evolution.
  • Shows specific acquirer trends by industry; consumer companies are less likely to change acquired brand, while energy and utilities sectors are fastest to rebrand.
  • Mergers of equals result in rebrands nearly 40 percent of the time.
  • More than half of all acquisitions are rebranded in the first three years of purchase.
  • Highly acquisitive companies transition acquired brands more quickly than those who complete fewer transactions.
  • Deal size matters: With deals under $1 billion, brands are changed 78 percent of the time, compared to 46 percent with transactions greater than $5 billion.

An infographic accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3f5ace4b-13c5-461b-afff-24202c7e0ebc

NEW YORK, Oct. 10, 2017 (GLOBE NEWSWIRE) -- In 2015 and 2016, mergers and acquisitions accounted for more than $8 trillion of business value. But while extensive due diligence and planning is given to financials and other factors during the deal-making process, brand strategy considerations are often overlooked or only evaluated post-M&A. This is due, in part, to a lack of relevant data for analysis. Nevertheless, the success of the transaction-and the amount of value that it generates, both in the short and long term-is a result of deciding if, when, or how to transition an acquired brand.

To better equip CEOs, boards of directors, and legal and financial advisors with strategies for making acquisitions, Landor, a leading global brand strategy and design firm, conducted the first in-depth quantitative analysis of M&A activity. Leveraging machine learning, Landor analyzed the behavior of S&P Global 100 companies over the past 10 years. While 74 percent of all companies rebranded the acquired asset within the first seven years, the data reveals more nuanced approaches to rebranding and specific trends by sector.

Acquirers within an industry behave similarly

The Landor M&A Brand Study uncovered distinct patterns by industry. More than any other sector, consumer companies (defined as consumer discretionary and consumer retail) are more likely to retain their acquired brands. Just under 60 percent of consumer companies rebrand, indicating that they want to retain the equity of their acquired brands and a portfolio of brands is a model this vertical finds successful. Coca-Cola's acquisition of the organic tea company Honest Tea is an example. The deal was completed in 2011, and the parent company has not made any significant branding changes.

The IT, financial services, health care, and energy sectors display the highest likelihood of changing an acquired brand, transitioning between 75 percent and 80 percent of acquisitions. These industries place more value on the acquirer than the acquired brand; the numbers demonstrate a propensity to start transitioning a brand as soon as the deal closes. Capital One completed its acquisition of ING Direct in February 2012 and soon after rebranded it Capital One 360. IBM has been on an acquisition spree over the past year, buying companies such as Clearleap, now known as IBM Cloud Video.

The energy and utilities sector is quickest to rebrand acquired companies, with 60 percent of brands changed within 12 months, according to the study. IT companies exhibit less urgency, transitioning half of acquired brands within the first year and 76 percent by year seven. Health care and financial services companies show similar behavior. Interestingly, telecommunications and industrial companies are slowest to change acquired brands, with a respective 8 percent and 24 percent of acquisitions transitioned within the first 12 months.

"In 2016, business leaders made thousands of decisions about what to do with acquired brands-but how do they really know which decisions are best? Our study clearly shows that different industries do different things. Being able to share quantitative trend data by sector over the last decade will finally enable CEOs, boards, and advisors to make more informed decisions about brand strategy when considering M&A," notes Lois Jacobs, CEO of Landor. "Whether a company is deciding if it should keep or divest a brand, how quickly to transition an acquired brand, or how to preserve brand equity, overlooking strategic brand decisions during the M&A process can negatively impact brand value and leave money on the table."

"There is no single, cookie-cutter approach to brand strategy during a merger or acquisition," says Louis Sciullo, executive director of financial services at Landor. "The ideal approach to brand acquisition strategy comes from a thorough understanding of the unique combination of factors specific to the acquiring and target companies. Now that real data is available, we can benchmark how individual companies and sectors treat M&A brand decisions-and layer that data into custom analyses bespoke to specific companies and deals."

Deal size, type, and volume correlate with likelihood of rebranding

Generally, the larger the transaction, the longer the transition time. Mergers of equals result in brand transitions a surprising 38 percent of the time. In theory, a merger of equals should be a simple conflation of the two existing brand names; for example, Alcatel-Lucent, DaimlerChrysler, and MillerCoors. But the fact that nearly 40 percent of mergers opt to rebrand reflects a desire to create a new, future-focused source of value-from the brand as well as the business.

A smaller deal is highly indicative of the likelihood of changing the acquired brand: 78 percent of transactions under $99 million were rebranded compared to only 46 percent of transactions over $5 billion. Highly acquisitive companies such as Alphabet and Microsoft display a greater propensity to rebrand, at a rate of more than 80 percent. Alphabet's brand architecture strategy is particularly interesting, with Google rebranding its corporate identity to facilitate M&A activity.

Landor's M&A database offers a range of insights

The study's database holds information on sector and company-specific brand transition factors during acquisitions, including target geography, strategic rationale, size of deal, type of deal, number of acquisitions made by company, and timeline for brand transition if implemented.

"Our study gives CEOs, corporate strategists, and M&A advisors a quantitative benchmark for comparison," says Sciullo. "It can help them see how competitors in their sector-and companies in other industries-have handled M&A, and which strategies have resulted in successful acquisitions. To maximize value for companies during an M&A, it's important that brand strategy be an ingredient throughout the deal process-not an afterthought."

For the study, Landor's methodology leveraged machine learning and big data to analyze 10 years of M&A activity from the S&P Global 100. The index was chosen because it measures the performance of multinational, blue-chip companies of major importance in the global equity markets. More than 2,300 acquisitions were taken into account, with brand strategy insights derived from more than 120,000 sources of unstructured data, including press releases, 3,000 web documents, 5,000 financial statements, and 2,000 investor presentations. The result is a definitive benchmark of M&A activity and its impact on brands and brand integrations of the leading companies across different industries, including Alphabet, Apple, Chevron, Dow Chemical, GE, JPMorgan Chase, PepsiCo, Pfizer, Procter & Gamble, Texas Instruments, Visa, and Vodafone.

For more information, contact:
Trevor Wade
Global Marketing Director
Trevor.Wade@Landor.com

About Landor
A global leader in brand consulting and design, Landor helps clients create agile brands that thrive in today's dynamic, disruptive marketplace.

Brand can accelerate the success of an M&A, so Landor partners closely with clients early on to ensure that brand is at the heart of integration strategies. Landor has helped companies such as Alcatel+Lucent, Alcoa+Arconic, Amoco+BP, Bayer+Covestro, DNV+GL, and Siemens+Primetals through mergers, acquisitions, and spin-offs.

Landor offers a range of M&A-specific services that include brand due diligence, brand valuation, portfolio optimization, future market modeling, and brand engagement. Our expertise also encompasses insights and analytics; strategy and positioning; brand architecture; innovation; identity; prototyping; naming and verbal identity; packaging; adaptation and implementation; environments and experiences; and new and interactive media.

Founded by Walter Landor in 1941, Landor pioneered many of the research, design, and consulting methods that are now standard in the branding industry. Today, Landor has 26 offices in 19 countries, working with a broad spectrum of world-famous brands, including Barclays, Bayer, BBC, BMW, BP, FedEx, GE, Kraft Heinz, Huawei Technologies, Marriott International, Nike, Pernod Ricard, Procter & Gamble, S&P Global, Samsung, Sony, and Taj Group. 

Landor is a member of WPP, the world's largest marketing and communications firm. For more information, please visit Landor.com and follow Landor on LinkedInFacebookTwitter, and Instagram.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Landor via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 201817.7.2018 22:30Pressmeddelande

LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2017 and quietus of directors; - Allocation of the financial year's results; - Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; - Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on June 27, 2017; - Authorization for the Board of Directors to grant share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma

Williams Scotsman Receives Competition Bureau Clearance for ModSpace Acquisition17.7.2018 22:15Pressmeddelande

BALTIMORE, July 17, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman"), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that, on July 16, 2018, the Canadian Competition Bureau issued a No Action Letter relating to Williams Scotsman's proposed acquisition of Modular Space Corporation ("ModSpace"). WillScot has now obtained the regulatory approvals required to complete the acquisition and continues to progress towards closing in the third quarter of 2018. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol "WSC." Williams Scotsman is a specialty rental services market leader providing innovative modular space and portable storage solutio

Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors17.7.2018 22:05Pressmeddelande

WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors of the Company. "Jeri brings a broad life sciences background to Minerva that includes high growth commercial biopharma, med-tech and data science companies," said William F. Doyle, Lead Independent Director of Minerva. "Her track record of delivering strategic and financial growth through execution, strategic partnering and multiple acquisitions will serve Minerva well as the Company completes five ongoing late-stage clinical trials with roluperidone, seltorexant and MIN-117." Ms. Hilleman is presently Chief Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public

Orion Biotechnology Awarded a $2M Grant from National Center for Research and Development to Fund Further Development of its HIV Microbicide17.7.2018 21:00Pressmeddelande

OTTAWA, July 17, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary, Orion Biotechnology Polska Sp. z o.o., was awarded a grant of $2M US dollars by the National Center for Research and Development . The grant will fund a project to advance development of the company's innovative microbicide candidate (OB-002H). Designed to prevent the transmission of HIV, OB-002H has the potential to address an urgent and growing need for an HIV prevention product that is affordable, appealing to use, and easily integrates into the lifestyles of people at risk for HIV infection regardless of age, sex or gender. The project is co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2: Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020. Orion Biotechnology will use the grant to complete IND enabling studies, advance OB-002H to

Greater Anglia Selects PowerPlan to Optimise Its Asset Investments17.7.2018 15:29Pressmeddelande

ATLANTA, July 17, 2018 (GLOBE NEWSWIRE) -- Greater Anglia, a UK-based train operating company, has selected PowerPlan's Asset Investment Optimization software suite to maximise its asset investments over a 40-year time period. Greater Anglia's long-term investment strategy includes a 40-year asset plan to meet its regulatory requirements. For what was historically built with manual processes and not easily tracked, the Asset Investment Optimization solution from PowerPlan will provide a comprehensive, auditable approach to help the company analyze different investment scenarios for impacts to risk, cost, timing and level of service and provide a defendable asset plan for the next four decades. "The condition of our assets drives our business," said Richard Turner, Head of Asset Management for Greater Anglia. "With PowerPlan, we can apply a fact-based methodology to prioritise investments, maximise their return and produce plans that communicate our asset strategy to internal and extern

Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 201817.7.2018 14:30Pressmeddelande

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 9268558, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum